PreComb Therapeutics AG is a privately held Swiss biotech company developing proprietary technology to enable evidence-based treatment decisions in cancer. The 3DTwin technology combines automated and clinically relevant drug testing with patient-specific biological tumor twins, AI-powered data analysis and response prediction. It’s tailored to be implemented directly in the clinic for oncology research and precision medicine.
PreComb is located in Hombrechtikon within the Greater Zurich Area. Close proximity to global leaders in engineering of Lab automation systems, to the technical and life-science universities of Zurich, Wädenswil and Rapperswil and to the Zurich Life-science cluster offers an attractive environment for the development of state-of-the-art diagnostic solutions.